Filing Flows › Bio-Rad Laboratories (BIO) › Q3 2026
Bio-Rad Laboratories (BIO) Q3 2026 earnings results (third quarter 2026)
10-Q filed Nov 4, 2026
Bio-Rad Laboratories (BIO) reported revenue of $656M for the third quarter 2026 (Q3 2026), +0.5% from a year earlier and +0.8% from the quarter before. Operating margin was -7.6%, net earnings $459M (69.9% of revenue).
Bio-Rad Laboratories, Q3 2026: revenue $656M (+0.5% year over year), operating margin -7.6%, net earnings $459M, operating cash flow $96.4M. The chart follows the revenue to costs, profit and cash.
| Q3 2026 | Amount | Q/Q | Y/Y |
|---|---|---|---|
| Revenue | $656M | +0.8% | +0.5% |
| Operating profit | −$49.7M | -168% | -176% |
| Net earnings | $459M | +23% | — |
| Operating cash flow | $96.4M | -2% | -20% |
| Free cash flow | $65.2M | -2% | -27% |
What changed
Revenue was $656.4M in Q3 2026, up 1% year over year and up 1% from the previous quarter. Clinical Diagnostics was the largest line at 61% of revenue. Clinical Diagnostics added $10.6M year over year (up 3%), 312% of the total change. Life Science declined 3%.
Gross margin was 50.1%, down 2.5 points from Q3 2025. Operating costs exceeded revenue by $49.7M, an operating margin of -7.6%. Operating expenses grew 36% against revenue growth of 1%. The fastest-growing cost line was SG&A (+24%). Net earnings were $458.6M. The effective tax rate was 14.9%. Non-operating items added $588.4M, 109% of pre-tax earnings, so the bottom line overstates operating performance.
Operating cash flow was $96.4M (down 20% year over year), 21% of net earnings. Non-cash charges added back $15.5M of share-based compensation. Working capital and other items used $377.7M. Capital expenditures of $31.2M left free cash flow of $65.2M.
Questions
What was Bio-Rad Laboratories' revenue in the third quarter 2026?
Bio-Rad Laboratories (BIO) reported revenue of $656M for the third quarter 2026 (Q3 2026), +0.5% from a year earlier and +0.8% from the quarter before.
Was Bio-Rad Laboratories profitable in the third quarter 2026?
Operating loss was $49.7M (-7.6% of revenue) and net earnings $459M.